Searched for
SANOFI INDIA STOCK
Dividends and bonus issues: 31 stocks turning ex-record date this week. Do you own any?As many as 31 companies, including HDFC Bank, Tata group firms and Brigade Enterprises, will turn ex-record date for dividends and bonus is...- Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...
- Bonus issue, stock split, dividend: 9 stocks to turn ex-record date next week, check detailsRail Vikas Nigam Limited shares rose 6% after securing a ₹967 crore railway order, strengthening its order book and boosting investor senti...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...
- Sunil Singhania-backed Abakkus Small Cap Fund first portfolio out since NFO; 42 stocks held, Karur Vysya Bank top betSunil Singhania backed Abakkus Mutual Fund has unveiled the maiden portfolio of its smallcap fund - Abakkus Small Cap Fund, following an in...
- Dispute with Sanofi settled, Panacea scrip soars to over 3-yr highPanacea Biotec has settled a patent dispute with Sanofi Healthcare India, leading to a rise in its stock. The Delhi High Court case involve...
- Sanofi Consumer Healthcare lists on stock exchanges after demerger, shares hit 5% upper circuit on day 1Shares of Sanofi Consumer Healthcare India made their market debut on Friday, listing on both the NSE and BSE. On its first day of trading,...
- Add Sanofi India, target price Rs 9170: ICICI SecuritiesSanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 19074.08 Crore) operating in Pharmaceutic...
- Hold Sanofi India, target price Rs 9170: ICICI SecuritiesSanofi India Ltd. key Products/Revenue Segments include Pharmaceutical Products, Sale of services, Other Operating Revenue, Export Incentiv...
- Sanofi India board OKs demerger of consumer health businessDrug firm Sanofi India on Wednesday said its board has approved the demerger of its consumer healthcare business into a separate entity. Th...
- Buy Sanofi India, target price Rs 6200: Sharekhan by BNP ParibasSanofi India, incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13232.93 Crore) operating in Pharmaceuticals s...
- Hold Sanofi India, target price Rs 6270: ICICI DirectSanofi India, incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13505.73 Crore) operating in Pharmaceuticals s...
- Buy Sanofi India, target price Rs 6738: ICICI SecuritiesSanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 12894.50 Crore) operating in Pharmaceutic...
- Hold Sanofi India, target price Rs 6885: ICICI DirectSanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13611.10 Crore) operating in Pharmaceutic...
- Buy Sanofi India, target price Rs 8500: Centrum BrokingSanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14647.01 Crore) operating in Pharmaceutic...
- Buy Sanofi India, target price Rs 9250: Sharekhan by BNP ParibasSanofi reported strong results for Q1CY22 with operating margins expanding 139 bps y-o-y and were better than estimated, leading to a PAT a...
- Sanofi India skids 2% on poor earnings scorecardSanofi India’s counter fell to a low of Rs 7,159 as against the previous close of Rs 7,280.40 on the National Stock Exchange.
- Sanofi India shares hit 52-week high on Q4 resultsThe stock witnessed similar movement on the NSE as well, where it opened at 7,549.95.
- Sanofi India stock likely to be re-rated on company's improving fundamentalsHowever, unlike other multinational pharmaceutical companies, Sanofi India was not analysts’ favourite for quite some time.
Load More
